List view / Grid view

Dr Joshua Greally (ADC Lead and Scientific Business Development at Sygnature Discovery)

 

article

Shifting the ADC focus from antibody to payload

While ADCs continue to attract attention in oncology, many developers…

6 June 2025 | By

While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is leading a shift in perspective, advocating for a payload-first approach through the company’s new platform, NewPath ADC. In this interview, he…